SCHEMBL2352089

SCHEMBL2352089

COc1cc(CNS(C)(=O)=O)c(Br)cc1C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.42
HPGD P15428 2/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
CYP3A4 P08684 1/20 0.37
ALOX15 P16050 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
GLA P06280 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36
KDM4E B2RXH2 1/20 0.35
HTT P42858 1/20 0.35
PKM P14618 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
FABP4 P15090 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11949275 0.80 CA12 (0.49) HTR2AMTNR1AMTNR1BTRPV1FABP4
SCHEMBL11949285 0.79 HTR2A (0.51) HTR2AHPGDLMNATP53CYP3A4
SCHEMBL2362794 0.75 HTR2A (0.36) HTR2AHPGDLMNATP53CYP3A4
SCHEMBL11957630 0.74 MTNR1A (0.52) HTR2AHPGDLMNATP53CYP3A4
SCHEMBL11949276 0.74 HTR2A (0.58) HTR2AHPGDLMNATP53CYP3A4
SCHEMBL1542560 0.74 HTR2A (0.50) HTR2AHPGDLMNATP53CYP3A4
SCHEMBL2362136 0.74 HTR2A (0.50) HTR2AHPGDLMNATP53CYP3A4
SCHEMBL2350725 0.73 CYP3A4 (0.34) HTR2AHPGDLMNATP53CYP3A4
SCHEMBL2362967 0.73 CYP3A4 (0.50) HTR2AHPGDLMNACYP3A4SMN1; SMN2
SCHEMBL11957632 0.72 MTNR1A (0.47) HTR2AHPGDLMNATP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US disclosed
EP-2350007-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-08-03 EP disclosed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US disclosed
WO-2010049331-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B HTR2A 2942/4885HPGD 1941/4885LMNA 3098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.